Table 3.
BMI-based subgroup analysis of sociodemographic and clinical characteristics in the olanzapine-treated group (n = 101).
| Normal weight (N = 50) | Overweight (N = 33) | Obesity (N = 18) | p ∗ | Multicomparison | |
|---|---|---|---|---|---|
| Age (years) | 26.2 ± 6.9 | 28.1 ± 5.2 | 28.5 ± 6.2 | 0.303 | — |
| Gender (F/M) | 29/21 | 19/15 | 8/6 | 0.982 | — |
| Body weight (kg) | 58.62 ± 7.14 | 68.29 ± 5.95 | 78.92 ± 12.14 | <0.001 | No < Ov < Ob |
| BMI | 21.86 ± 1.28 | 25.74 ± 1.18 | 30.56 ± 2.02 | <0.001 | No < Ov < Ob |
| Physical activity indexa | 5.10 ± 4.52 | 4.45 ± 4.04 | 5.64 ± 4.27 | 0.887 | — |
| Smoking (Y/N) | 15/35 | 8/25 | 4/10 | 0.847 | |
| Drinking (Y/N) | 11/39 | 5/28 | 1/13 | 0.393 | — |
| Dosage (mg/d)b | 422.5 ± 137.6 | 384.9 ± 129.2 | 485.71 ± 183.3 | 0.087 | — |
| Duration of olanzapine use (year) | 2.7 ± 2.1 | 2.4 ± 1.9 | 2.5 ± 2.4 | 0.892 | — |
| Duration of illness (year) | 5.6 ± 4.7 | 5.8 ± 4.9 | 4.1 ± 3.9 | 0.585 | — |
| PANSS | 90.2 ± 10.3 | 89.4 ± 11.2 | 92.6 ± 13.7 | 0.429 | — |
aPhysical activity index = intensity × duration × times. bOlanzapine medication dosages were transformed to chlorpromazine equivalent dosages. ∗Comparison of sociodemographic and clinical characteristics among the normal weight, overweight, and obesity subgroups.